✦ LIBER ✦

Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival

✍ Scribed by Kevin R Flaherty; Galen B Toews; Joseph P Lynch III; Ella A Kazerooni; Barry H Gross; Robert L Strawderman III; Kamala Hariharan; Andrew Flint; Fernando J Martinez

Book ID: 117013251
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 101 KB
Volume: 110
Category: Article
ISSN: 1555-7162
DOI: 10.1016/s0002-9343(00)00711-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Serum LDH: a marker of disease activity

Serum LDH: a marker of disease activity and its response to therapy in idiopathic pulmonary fibrosis

✍ M. van Krugten; N.A.M. Cobben; R.J.S. Lamers; M.P. van Dieijen-Visser; Sj.Sc. Wa 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 354 KB

Pre-treatment serum levels of tumour mar

Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival

✍ K.V. Albuquerque; M.R. Price; R.A. Badley; I. Jonrup; D. Pearson; R.W. Blamey; J 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 409 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB